US 7994307
RNAi modulation of the BCR-ABL fusion gene and uses thereof
granted A61PA61P31/00A61P35/00
Quick answer
US patent 7994307 (RNAi modulation of the BCR-ABL fusion gene and uses thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Aug 04 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Aug 09 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 04 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61P, A61P31/00, A61P35/00, A61P35/02, A61P43/00